Dr Nagasaka on the Efficacy of Repotrectinib in Locally Advanced/Metastatic ROS1+ NSCLC

Misako Nagasaka, MD, discusses key findings from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Related Keywords

California ,United States ,Irvine School ,Misako Nagasaka ,University Of California ,Division Of Hematology Oncology ,Irvine School Of Medicine ,D ,Trident 1 Trial ,Nct03093116 ,Repotrectinib ,Patients With Locally Advanced Or Metastatic Ros1 Positive Non Small Cell Lung Cancer ,